Durhane Wong-Rieger, the president and CEO of the Canadian Organization for Rare Disorders, discusses the challenges that Canadians with rare disorders face in getting access to drugs and the risk that single-payer pharmacare exacerbates them by focusing too much on cost control and too little on the benefits of personalized medicine.
This episode was made possible by the Canadian Life and Health Insurance Association and listeners like you.
